{
    "2020-10-22": [
        [
            {
                "time": "",
                "original_text": "【财报智读】健帆生物：2020年前三季度总收入13.15亿元",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "财报",
                        "总收入",
                        "2020年"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "健帆生物(300529)2020年三季报点评：环比进一步加速 刚需持续高增长",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "三季报",
                        "环比加速",
                        "刚需",
                        "高增长"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "79股获券商买入评级，招商积余目标涨幅达72.83%",
                "features": {
                    "keywords": [
                        "券商",
                        "买入评级",
                        "招商积余",
                        "目标涨幅"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "房地产"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "公募基金三季度调仓初露端倪，生物医药板块仍被高配",
                "features": {
                    "keywords": [
                        "公募基金",
                        "调仓",
                        "生物医药",
                        "高配"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}